Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson’s disease
Article first published online: 25 OCT 2010
© 2010 John Wiley & Sons A/S
Acta Neurologica Scandinavica
Volume 124, Issue 3, pages 211–214, September 2011
How to Cite
Evidente, V. G. H., Premkumar, A. P., Adler, C. H., Caviness, J. N., Driver-Dunckley, E. and Lyons, M. K. (2011), Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson’s disease. Acta Neurologica Scandinavica, 124: 211–214. doi: 10.1111/j.1600-0404.2010.01455.x
- Issue published online: 8 AUG 2011
- Article first published online: 25 OCT 2010
- Accepted for publication September 29, 2010
- Deep brain stimulation;
- Parkinson’s disease;
Evidente VGH, Premkumar AP, Adler CH, Caviness JN, Driver-Dunckley E, Lyons MK. Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson’s disease. Acta Neurol Scand: 2011: 124: 211–214. © 2010 John Wiley & Sons A/S.
Objective – To compare the medication dose reduction between deep brain stimulation (DBS) of the globus pallidus interna (GPi) vs subthalamic nucleus (STN) in matched patients with Parkinson’s disease (PD).
Materials and methods – Records of 12 patients with PD who underwent GPi-DBS at our institution from 2002 to 2008 were matched by pre-operative PD medication doses and pre-operative motor Unified Parkinson’s Disease Rating Scale (UPDRS) scores to 12 cases of STN-DBS. PD medication doses were converted to levodopa equivalent doses (LEDs).
Results – GPi and STN groups had similar mean pre-operative LEDs and motor UPDRS scores. At 6 months post-DBS, there was no significant difference in percent reduction in LEDs between the GPi (47.95%) and STN (37.47%) groups (P = 0.52). The mean post-operative ‘medication off/stimulation on’ motor UPDRS scores did not differ significantly between GPi (15.33) and STN (16.25) groups (P = 0.74). The mean percent reduction in motor UPDRS scores was also similar between GPi (58.44%) and STN (58.98%) patients (P = 0.94).
Conclusions – We conclude that in disease-matched patients with PD undergoing DBS, both GPi and STN may result in similar reduction in PD medication doses.